COMMUNIQUÉS West-GlobeNewswire

UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT BLUEPOINT BRUSSELS
23/03/2018
*** Unofficial English translation - For convenience purposes only *** UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) (" UCB SA/NV " or [...]
UCB: CONVOCATION À L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES QUI SE TIENDRA À BLUEPOINT BRUSSELS
23/03/2018
UCB - société anonyme Allée de la Recherche 60, 1070 Bruxelles n° d'entreprise 0403.053.608 (RPM Bruxelles) (« UCB SA » ou la « Société ») Convocation à l'Assemblée Générale des actionnaires qui se tiendra à BLUEPOINT [...]
INNATE PHARMA : Expansion of mCRC cohort in Phase I trial evaluating monalizumab with Imfinzi
23/03/2018
Partner MedImmune expands colorectal cancer patient cohort in ongoing PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI ® (DURVALUMAB) Additional expansion cohorts to explore the safety and efficacy of [...]
INNATE PHARMA : Extension de cohorte dans la Phase I évaluant monalizumab et Imfinzi dans le cancer colorectal
23/03/2018
MedImmune Étend l'essai de phase I en cours Évaluant MONALIZUMAB en combinaison avec Imfinzi ® (DURVALUMAB) et inclut de nouvelles cohortes de patients atteints d'un cancer colorectal Les cohortes additionnelles [...]
Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
23/03/2018
CRANBURY, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the oral small molecule pharmacological [...]
Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
23/03/2018
SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel Phase I clinical [...]
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
23/03/2018
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate siponimod also had beneficial [...]
CV Sciences, Inc. to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 29, 2018
23/03/2018
LAS VEGAS, March 22, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. , (OTCQB:CVSI) preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, today announced that it is scheduled to host a [...]
AFA: How Federal Spending Deal Impacts Individuals with Alzheimer’s
22/03/2018
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- Boost to NIA/NIH Funding The omnibus federal spending deal, currently being considered by Congress, will deliver a $414 million funding increase for Alzheimer’s disease [...]
Vistin Pharma ASA : Key information for the subsequent repair issue
22/03/2018
Reference is made to the stock exchange notice from Vistin Pharma ASA earlier today, 22 March 2018, regarding a subsequent repair issue of approximately NOK 50 million. Key information for the subsequent repair issue is [...]
Vistin Pharma ASA : SUCCESSFULLY COMPLETED PRIVATE PLACEMENT
22/03/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR [...]
Tergus Pharma announces the Acquisition of EnDev Labs
22/03/2018
RESEARCH TRIANGLE PARK, N.C., March 22, 2018 (GLOBE NEWSWIRE) -- Tergus Pharma, LLC, the leading global provider of dermatology Contract Research Organization (CRO) Services, today announced that it has acquired EnDev [...]
Healthcare Special Opportunities Fund Announces NAV Correction
22/03/2018
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 22, 2018 (GLOBE NEWSWIRE) -- (TSX:MDS.UN) – LDIC Inc. (the “ Manager ”), the manager of the Healthcare Special [...]
iKang Announces Unaudited Financial Results for the Fiscal Third Quarter Ended December 31, 2017
22/03/2018
BEIJING, March 22, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG ), major provider in China’s fast growing private preventive healthcare services market, today announced [...]
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore
22/03/2018
MENLO PARK, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB ), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S [...]
ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update
22/03/2018
WESTMINSTER, Colo., March 22, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO ), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for [...]
Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
22/03/2018
GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program [...]
Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences
22/03/2018
SOUTH SAN FRANCISCO, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)
22/03/2018
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, [...]

Pages